Biomarkers significantly reduce clinical trial failures and increase the likelihood of drug approval. However, they are used in all phases of only 7.1% of clinical trials due to an inefficient and time-consuming adoption process. This inefficiency is largely driven by incomplete and convoluted biomarker databases, which provide no more than 61% of relevant information and fail to deliver integrated insights.
The AI-assisted biomarker selection platform we developed empowers scientists to accelerate biomarker adoption. By combining exhaustive data curation, advanced AI-driven analysis, and an intuitive interface, the platform simplifies and optimizes the selection process. It delivers integrated insights and figures, enabling scientists to identify and adopt the most suitable biomarkers quickly and confidently.
Outcome
This solution dramatically increases the speed and quality of drug development. Scientists can streamline research processes, reduce resource expenditure, and deliver new medicines to patients up to 50% faster by 2025, addressing a critical bottleneck in clinical trials while improving outcomes across the pharmaceutical industry.
Check out the deck here
